I
Power Law company profile
Innovent Biologics
Biotech & Life Sciences · Suzhou Shi, China · Founded 2011 · IPO 2018 Decacorn
Valuation
$16B
Market cap · Apr/2026
Revenue
$1.79B
Latest reported FY
Global footprint
Where Innovent Biologics has talent and traffic
Web traffic by country
21K
monthly visits
across markets
across markets
🇺🇸 United States21%
🇨🇳 China16.7%
🇩🇰 Denmark16.2%
🇭🇰 Hong Kong15.7%
🏳️ Korea12.9%
Patent intelligence
$76M patent portfolio · 148 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$76M
0.49% of market cap · 26.5× smaller than top peer Ablynx ($2B)
148 active patent families
Where Innovent Biologics innovates
Molecular biologyAntiendomysial antibodiesPharmaceutical drugImmunologyNucleic acid
Below peer median on Strategic, Market
Quality vs same-sector peers
Innovent Biologics on the five Patsnap quality dimensions
Innovent Biologics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Innovent Biologics concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Innovent Biologics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Innovent Biologics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.